Profile data is unavailable for this security.
About the company
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-126.86m
- Incorporated2018
- Employees126.00
- LocationErasca Inc10835 Road To The Cure, Suite 140SAN DIEGO 92121-1130United StatesUSA
- Phone+1 (858) 465-6511
- Fax+1 (302) 636-5454
- Websitehttps://www.erasca.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics Inc | 87.00k | -292.30m | 712.67m | 232.00 | -- | 1.26 | -- | 8,191.65 | -1.78 | -1.78 | 0.0005 | 2.71 | 0.0001 | -- | -- | 375.00 | -43.85 | -28.46 | -47.04 | -30.21 | -- | -- | -335,973.60 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Stoke Therapeutics Inc | 7.85m | -108.53m | 713.00m | 110.00 | -- | 4.53 | -- | 90.89 | -2.42 | -2.42 | 0.1747 | 3.02 | 0.0322 | -- | 31.19 | 71,318.18 | -44.57 | -31.62 | -51.70 | -33.92 | -- | -- | -1,383.40 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Replimune Group Inc | 0.00 | -215.79m | 713.10m | 331.00 | -- | 1.74 | -- | -- | -3.24 | -3.24 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -38.05 | -29.08 | -40.71 | -30.56 | -- | -- | -- | -- | -- | -- | 0.1593 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| Arbutus Biopharma Corp | 12.99m | -74.39m | 713.35m | 73.00 | -- | 5.94 | -- | 54.93 | -0.4393 | -0.4393 | 0.0766 | 0.6362 | 0.0761 | -- | 5.41 | 177,890.40 | -43.56 | -52.62 | -50.25 | -58.11 | -- | -- | -572.81 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Scholar Rock Holding Corp | 0.00 | -183.26m | 713.80m | 150.00 | -- | 3.90 | -- | -- | -2.09 | -2.09 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.98 | -38.14 | -70.72 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2151 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| Zymeworks Inc | 50.46m | -125.97m | 715.53m | 275.00 | -- | 1.65 | -- | 14.18 | -1.79 | -1.79 | 0.7086 | 6.15 | 0.0874 | -- | 1.03 | 185,529.40 | -21.82 | -22.58 | -24.45 | -26.90 | -- | -- | -249.63 | -91.17 | -- | -- | 0.0002 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Wave Life Sciences Ltd | 112.91m | -61.67m | 723.83m | 266.00 | -- | 28.47 | -- | 6.41 | -0.5152 | -0.5152 | 0.9985 | 0.2719 | 0.4494 | -- | -- | 424,488.70 | -24.54 | -56.98 | -60.43 | -102.38 | -- | -- | -54.61 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| SAGE Therapeutics Inc | 91.06m | -503.14m | 731.21m | 487.00 | -- | 1.04 | -- | 8.03 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Prime Medicine Inc | 591.00k | -204.50m | 754.99m | 234.00 | -- | 3.10 | -- | 1,277.49 | -2.17 | -2.17 | 0.0062 | 2.03 | 0.0019 | -- | -- | 2,525.64 | -65.09 | -- | -70.51 | -- | -- | -- | -34,601.86 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Erasca Inc | 0.00 | -126.86m | 759.17m | 126.00 | -- | 1.67 | -- | -- | -0.8423 | -0.8423 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -30.29 | -- | -32.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
| Lexicon Pharmaceuticals Inc | 2.31m | -193.58m | 769.88m | 285.00 | -- | 1.82 | -- | 333.14 | -0.8257 | -0.8257 | 0.0098 | 1.17 | 0.008 | -- | 2.59 | 8,108.77 | -66.76 | -24.41 | -72.21 | -29.01 | 94.98 | 98.49 | -8,376.55 | -84.92 | 15.56 | -11.46 | 0.2569 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| Travere Therapeutics Inc | 155.72m | -415.73m | 783.37m | 380.00 | -- | 10.57 | -- | 5.03 | -5.32 | -2.00 | 2.04 | 0.9732 | 0.2116 | 1.57 | 7.04 | 409,800.00 | -56.49 | -36.95 | -71.19 | -44.77 | 94.34 | 95.92 | -266.96 | -165.79 | 2.75 | -- | 0.836 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Savara Inc | 0.00 | -64.49m | 785.94m | 37.00 | -- | 5.42 | -- | -- | -0.3848 | -0.3848 | 0.00 | 0.8819 | 0.00 | -- | -- | 0.00 | -44.84 | -36.86 | -47.26 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.1782 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Perspective Therapeutics Inc | -304.00k | -48.91m | 805.85m | 116.00 | -- | 3.05 | -- | -- | -1.62 | -1.97 | -0.0092 | 3.92 | -0.0015 | -- | -- | -2,620.69 | -24.10 | -- | -25.46 | -- | -- | -- | -- | -- | -- | -- | 0.0074 | -- | -- | -- | -- | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -99.34m | 807.13m | 75.00 | -- | 3.41 | -- | -- | -2.02 | -2.02 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -43.24 | -30.06 | -48.01 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -121.21m | 807.82m | 116.00 | -- | 1.86 | -- | -- | -2.91 | -2.91 | 0.00 | 9.48 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
Data as of Jul 22 2024. Currency figures normalised to Erasca Inc's reporting currency: US Dollar USD
18.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Suvretta Capital Management LLCas of 17 May 2024 | 13.77m | 5.30% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.35m | 2.45% |
| Armistice Capital LLCas of 31 Mar 2024 | 6.17m | 2.38% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 4.72m | 1.82% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 4.27m | 1.64% |
| Prosight Management LPas of 31 Mar 2024 | 3.66m | 1.41% |
| PFM Health Sciences LPas of 31 Mar 2024 | 2.54m | 0.98% |
| Sio Capital Management LLCas of 31 Mar 2024 | 2.43m | 0.93% |
| Schroder Investment Management Ltd.as of 31 Mar 2024 | 1.93m | 0.74% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.89m | 0.73% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
